Literature DB >> 12704343

IL-13 receptors and signaling pathways: an evolving web.

Gurjit K Khurana Hershey1.   

Abstract

IL-13 is an immunoregulatory cytokine secreted predominantly by activated T(H)2 cells. Over the past several years, it has become evident that IL-13 is a key mediator in the pathogenesis of allergic inflammation. IL-13 shares many functional properties with IL-4, stemming from the fact that they share a common receptor subunit, the alpha subunit of the IL-4 receptor (IL-4Ralpha). Characterization of IL-13-deficient mice, IL-4-deficient mice, and IL-4 receptor alpha-deficient (IL-4Ralpha(-/-)) mice have demonstrated nonredundant roles for IL-13. IL-13 mediates its effects by interacting with a complex receptor system comprised of IL-4Ralpha and two IL-13 binding proteins, IL-13Ralpha1 and IL-13Ralpha2. IL-13 receptors are expressed on human B cells, basophils, eosinophils, mast cells, endothelial cells, fibroblasts, monocytes, macrophages, respiratory epithelial cells, and smooth muscle cells. However, functional IL-13 receptors have not been demonstrated on human or mouse T cells. Thus unlike IL-4, IL-13 does not appear to be important in the initial differentiation of CD4 T cells into T(H)2-type cells but rather appears to be important in the effector phase of allergic inflammation. This is further supported by many in vivo observations, including that administration of IL-13 resulted in allergic inflammation, tissue-specific overexpression of IL-13 in the lungs of transgenic mice resulted in airway inflammation and mucus hypersecretion, IL-13 blockade abolished allergic inflammation independently of IL-4, and IL-13 appears to be more important than IL-4 in mucus hypersecretion. Given the importance of IL-13 as an effector molecule, regulation at the level of its receptors might be an important mechanism of modulating IL-13 responses and thus propagation of the allergic response. Accordingly, IL-13 is an attractive, novel therapeutic target for pharmacologic intervention in allergic disorders. This review will summarize the current understanding of the IL-13 receptors and signaling pathways, emphasizing recent observations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704343     DOI: 10.1067/mai.2003.1333

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  197 in total

1.  Oxidant signaling for interleukin-13 gene expression in lung smooth muscle cells.

Authors:  Geetanjali Bansal; Chi-Ming Wong; Lingling Liu; Yuichiro J Suzuki
Journal:  Free Radic Biol Med       Date:  2012-02-25       Impact factor: 7.376

2.  An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males.

Authors:  Chad K Oh; Raffaella Faggioni; Feng Jin; Lorin K Roskos; Bing Wang; Claire Birrell; Rosamund Wilson; Nestor A Molfino
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

3.  Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Authors:  Christoph Spiess; Jack Bevers; Janet Jackman; Nancy Chiang; Gerald Nakamura; Michael Dillon; Hongbin Liu; Patricia Molina; J Michael Elliott; Whitney Shatz; Justin M Scheer; Glen Giese; Josefine Persson; Yin Zhang; Mark S Dennis; James Giulianotti; Prateek Gupta; Dorothea Reilly; Enzo Palma; Jianyong Wang; Eric Stefanich; Heleen Scheerens; Germaine Fuh; Lawren C Wu
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

4.  Glycomacropeptide administration attenuates airway inflammation and remodeling associated to allergic asthma in rat.

Authors:  Nuria Renata Roldán; Mariela Jiménez; Daniel Cervantes-García; Estefanía Marín; Eva Salinas
Journal:  Inflamm Res       Date:  2016-01-11       Impact factor: 4.575

5.  Th2 signals induce epithelial injury in mice and are compatible with the biliary atresia phenotype.

Authors:  Jun Li; Kazuhiko Bessho; Pranavkumar Shivakumar; Reena Mourya; Sujit Kumar Mohanty; Jorge L Dos Santos; Irene K Miura; Gilda Porta; Jorge A Bezerra
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

6.  A₁ adenosine receptor deficiency or inhibition reduces atherosclerotic lesions in apolipoprotein E deficient mice.

Authors:  Bunyen Teng; Jonathan D Smith; Michael E Rosenfeld; Peggy Robinet; Mary E Davis; R Ray Morrison; S Jamal Mustafa
Journal:  Cardiovasc Res       Date:  2014-02-12       Impact factor: 10.787

7.  Airway and lung pathology due to mucosal surface dehydration in {beta}-epithelial Na+ channel-overexpressing mice: role of TNF-{alpha} and IL-4R{alpha} signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment.

Authors:  Alessandra Livraghi; Barbara R Grubb; Elizabeth J Hudson; Kristen J Wilkinson; John K Sheehan; Marcus A Mall; Wanda K O'Neal; Richard C Boucher; Scott H Randell
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

8.  Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.

Authors:  Stefan Fichtner-Feigl; Masaki Terabe; Atsushi Kitani; Cheryl A Young; Ivan Fuss; Edward K Geissler; Hans-Jürgen Schlitt; Jay A Berzofsky; Warren Strober
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

Authors:  Cory Allen; Georgia Paraskevakou; Ianko Iankov; Caterina Giannini; Mark Schroeder; Jann Sarkaria; Mark Schroeder; Raj K Puri; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

10.  Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Ralpha, IL-13Ralpha1, and gammac regulates relative cytokine sensitivity.

Authors:  Ilkka S Junttila; Kiyoshi Mizukami; Harold Dickensheets; Martin Meier-Schellersheim; Hidehiro Yamane; Raymond P Donnelly; William E Paul
Journal:  J Exp Med       Date:  2008-10-13       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.